You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBetaxolol
Accession NumberDB00195  (APRD00245)
TypeSmall Molecule
GroupsApproved
DescriptionA cardioselective beta-1-adrenergic antagonist with no partial agonist activity. [PubChem]
Structure
Thumb
Synonyms
1-(4-(2-(Cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol
1-(Isopropylamino)-3-[P-(cyclopropylmethoxyethyl)phenoxy]-2-propanol
Betaxololum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Betaxolol HydrochlorideSolution / drops5.6 mg/mLOphthalmicSandoz Inc2000-05-15Not applicableUs
Betoptic LiqLiquid0.5 %OphthalmicAlcon Canada Inc1986-12-311997-07-31Canada
Betoptic SSuspension / drops2.8 mg/mLOphthalmicAlcon Laboratories, Inc.1996-01-15Not applicableUs
Betoptic S Oph Sus 0.25%Suspension.25 %OphthalmicAlcon Canada Inc1994-12-31Not applicableCanada
Novo-betaxololLiquid0.5 %OphthalmicNovopharm LimitedNot applicableNot applicableCanada
Sandoz BetaxololSolution0.5 %OphthalmicSandoz Canada Incorporated1998-11-27Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BetaxololTablet, film coated20 mg/1OralEpic Pharma LLC2010-07-20Not applicableUs
BetaxololTablet, film coated10 mg/1OralGolden State Medical Supply, Inc.2008-06-27Not applicableUs
BetaxololTablet, film coated10 mg/1OralMarlex Pharmaceuticals Inc2016-07-01Not applicableUs
BetaxololTablet, film coated20 mg/1OralGolden State Medical Supply, Inc.2008-06-27Not applicableUs
BetaxololTablet, film coated20 mg/1OralMarlex Pharmaceuticals Inc2016-07-01Not applicableUs
BetaxololSolution / drops5 mg/mLOphthalmicAkorn, Inc.2003-04-01Not applicableUs
BetaxololTablet, film coated10 mg/1OralEpic Pharma LLC2010-07-20Not applicableUs
BetaxololTablet, film coated10 mg/1OralPhysicians Total Care, Inc.2003-10-07Not applicableUs
Betaxolol HydrochlorideTablet, coated10 mg/1OralKvk Tech, Inc.2011-11-02Not applicableUs
Betaxolol HydrochlorideTablet, coated20 mg/1OralKvk Tech, Inc.2011-11-02Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BetaxonNot Available
BetopticNot Available
KerloneNot Available
Brand mixtures
NameLabellerIngredients
Betoptic/piloAlcon Canada Inc
Salts
Name/CASStructureProperties
Betaxolol Hydrochloride
63659-19-8
Thumb
  • InChI Key: CHDPSNLJFOQTRK-UHFFFAOYNA-N
  • Monoisotopic Mass: 343.191421538
  • Average Mass: 343.889
DBSALT000328
Categories
UNIIO0ZR1R6RZ2
CAS number63659-18-7
WeightAverage: 307.4278
Monoisotopic: 307.214743799
Chemical FormulaC18H29NO3
InChI KeyNWIUTZDMDHAVTP-UHFFFAOYSA-N
InChI
InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3
IUPAC Name
1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-[(propan-2-yl)amino]propan-2-ol
SMILES
CC(C)NCC(O)COC1=CC=C(CCOCC2CC2)C=C1
Pharmacology
IndicationFor the management of hypertension.
Structured Indications
PharmacodynamicsBetaxolol is a competitive, beta(1)-selective (cardioselective) adrenergic antagonist. Betaxolol is used to treat hypertension, arrhythmias, coronary heart disease, glaucoma, and is also used to reduce non-fatal cardiac events in patients with heart failure. Activation of beta(1)-receptors (located mainly in the heart) by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Drugs such as betaxolol that block these receptors therefore have the reverse effect: they lower the heart rate and blood pressure and hence are used in conditions when the heart itself is deprived of oxygen. They are routinely prescribed in patients with ischemic heart disease. In addition, beta(1)-selective blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. Betaxolol is lipophilic and exhibits no intrinsic sympathomimetic activity (ISA) or membrane stabilizing activity.
Mechanism of actionBetaxolol selectively blocks catecholamine stimulation of beta(1)-adrenergic receptors in the heart and vascular smooth muscle. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. Betaxolol can also competitively block beta(2)-adrenergic responses in the bronchial and vascular smooth muscles, causing bronchospasm.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Beta-2 adrenergic receptorProteinunknown
antagonist
HumanP07550 details
Related Articles
AbsorptionAbsorption of an oral dose is complete. There is a small and consistent first-pass effect resulting in an absolute bioavailability of 89% ± 5% that is unaffected by the concomitant ingestion of food or alcohol.
Volume of distributionNot Available
Protein binding50%
Metabolism

Primarily hepatic. Approximately 15% of the dose administered is excreted as unchanged drug, the remainder being metabolites whose contribution to the clinical effect is negligible.

Route of eliminationNot Available
Half life14-22 hours
ClearanceNot Available
ToxicityOral LD50s are 350 to 400 mg betaxolol/kg in mice and 860 to 980 mg/kg in rats. Predicted symptoms of overdose include bradycardia, congestive heart failure, hypotension, bronchospasm, and hypoglycemia.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Betaxolol Action PathwayDrug actionSMP00299
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Betaxolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Betaxolol.Experimental
AbirateroneThe serum concentration of Betaxolol can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Betaxolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Betaxolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Betaxolol.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Betaxolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideBetaxolol may increase the hypoglycemic activities of Acetohexamide.Withdrawn
AcetovanilloneAcetovanillone may decrease the antihypertensive activities of Betaxolol.Investigational
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Betaxolol.Approved
AcetyldigitoxinBetaxolol may increase the bradycardic activities of Acetyldigitoxin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Betaxolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Betaxolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Experimental, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Betaxolol.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Betaxolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Betaxolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Betaxolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Betaxolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Betaxolol is combined with Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Betaxolol.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Betaxolol.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Betaxolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Betaxolol.Approved
AmbrisentanBetaxolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateBetaxolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental
AmifostineBetaxolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Amiloride.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Betaxolol.Approved, Withdrawn
AminophyllineBetaxolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Betaxolol.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Betaxolol.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Betaxolol.Approved, Illicit
AmodiaquineThe metabolism of Betaxolol can be decreased when combined with Amodiaquine.Approved
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Betaxolol.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Betaxolol.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Betaxolol is combined with Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Betaxolol.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Betaxolol.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Betaxolol is combined with Amyl Nitrite.Approved
AnisodamineAnisodamine may decrease the antihypertensive activities of Betaxolol.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Betaxolol.Approved
AnvirzelBetaxolol may increase the bradycardic activities of Anvirzel.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Betaxolol.Approved
ArbutamineBetaxolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Arecoline.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Betaxolol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Betaxolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Betaxolol.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Betaxolol.Approved, Withdrawn
AtenololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Atenolol.Approved
AtomoxetineThe metabolism of Betaxolol can be decreased when combined with Atomoxetine.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Betaxolol.Withdrawn
AzelastineThe metabolism of Azelastine can be decreased when combined with Betaxolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Azilsartan medoxomil.Approved
AzithromycinThe metabolism of Betaxolol can be decreased when combined with Azithromycin.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BambuterolBetaxolol may decrease the bronchodilatory activities of Bambuterol.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Betaxolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Betaxolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Betaxolol.Withdrawn
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Betaxolol.Withdrawn
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Betaxolol.Approved
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Betaxolol.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Betaxolol.Approved, Withdrawn
BeractantBetaxolol may increase the bradycardic activities of Beractant.Approved
BethanecholThe risk or severity of adverse effects can be increased when Betaxolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
Betulinic AcidBetulinic Acid may decrease the antihypertensive activities of Betaxolol.Investigational
BimatoprostBetaxolol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Betaxolol.Investigational
BortezomibThe metabolism of Betaxolol can be decreased when combined with Bortezomib.Approved, Investigational
BosentanBetaxolol may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Betaxolol.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Betaxolol.Approved
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Betaxolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Betaxolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Betaxolol.Approved
BucillamineBucillamine may decrease the antihypertensive activities of Betaxolol.Investigational
BucindololBetaxolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Betaxolol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Bumetanide.Approved
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Betaxolol.Approved, Investigational
BupranololBetaxolol may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Betaxolol.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Betaxolol can be decreased when combined with Bupropion.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Betaxolol.Approved, Investigational
CabergolineBetaxolol may increase the vasoconstricting activities of Cabergoline.Approved
CaffeineThe metabolism of Betaxolol can be decreased when combined with Caffeine.Approved
CalfactantBetaxolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Betaxolol is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Betaxolol is combined with Candesartan.Approved
CandoxatrilBetaxolol may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Betaxolol is combined with Carbachol.Approved
CarbamazepineThe metabolism of Betaxolol can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Betaxolol is combined with Carbetocin.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Betaxolol.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Betaxolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Betaxolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Carteolol.Approved
CarvedilolBetaxolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Betaxolol.Experimental
CelecoxibThe metabolism of Betaxolol can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololBetaxolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Betaxolol.Approved, Vet Approved
CeritinibBetaxolol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Betaxolol.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Betaxolol.Approved, Illicit
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Betaxolol.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Betaxolol.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Betaxolol.Approved, Vet Approved
ChlorpropamideBetaxolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Betaxolol is combined with Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Betaxolol.Approved
CholecalciferolThe metabolism of Betaxolol can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Cilnidipine.Approved
CilostazolThe metabolism of Cilostazol can be decreased when combined with Betaxolol.Approved
CimetidineThe metabolism of Betaxolol can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Betaxolol can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Betaxolol.Approved
CitalopramThe metabolism of Betaxolol can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Betaxolol can be decreased when combined with Clemastine.Approved
ClenbuterolBetaxolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Clevidipine.Approved
ClobazamThe metabolism of Betaxolol can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Clofarabine.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Betaxolol.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Betaxolol.Approved
ClotrimazoleThe metabolism of Betaxolol can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Betaxolol.Approved
CobicistatThe serum concentration of Betaxolol can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Betaxolol can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Betaxolol.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Betaxolol is combined with Conivaptan.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Betaxolol.Vet Approved
CrizotinibBetaxolol may increase the bradycardic activities of Crizotinib.Approved
CryptenamineBetaxolol may increase the hypotensive activities of Cryptenamine.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Betaxolol.Investigational
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Betaxolol.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Betaxolol.Approved, Investigational
CyclothiazideBetaxolol may increase the hypotensive activities of Cyclothiazide.Approved
Cyproterone acetateThe serum concentration of Betaxolol can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneD-Limonene may decrease the antihypertensive activities of Betaxolol.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Betaxolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Betaxolol can be increased when it is combined with Dapoxetine.Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Betaxolol.Approved, Investigational
DarunavirThe serum concentration of Betaxolol can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Betaxolol.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Betaxolol.Approved
DecamethoniumDecamethonium may increase the bradycardic activities of Betaxolol.Approved
DeferasiroxThe serum concentration of Betaxolol can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Betaxolol can be decreased when combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Betaxolol.Approved
DeserpidineBetaxolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Betaxolol is combined with Desflurane.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Betaxolol.Approved
DeslanosideBetaxolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Betaxolol can be increased when it is combined with Desvenlafaxine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Betaxolol.Approved, Illicit, Withdrawn
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Betaxolol.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Betaxolol.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Betaxolol.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Betaxolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Betaxolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Betaxolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Diclofenamide.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Betaxolol.Approved
DigitoxinBetaxolol may increase the bradycardic activities of Digitoxin.Approved
DigoxinBetaxolol may increase the bradycardic activities of Digoxin.Approved
DihydralazineBetaxolol may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Betaxolol.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Betaxolol is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Betaxolol is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Betaxolol.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Betaxolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Betaxolol.Approved
DobutamineBetaxolol may decrease the bronchodilatory activities of Dobutamine.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Betaxolol.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Betaxolol.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the bradycardic activities of Betaxolol.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Betaxolol.Approved
DorzolamideBetaxolol may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinBetaxolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Betaxolol.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Betaxolol.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Betaxolol.Approved, Investigational
DronedaroneDronedarone may increase the bradycardic activities of Betaxolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Betaxolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Investigational
DuloxetineBetaxolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Betaxolol.Investigational
DyphyllineBetaxolol may decrease the bronchodilatory activities of Dyphylline.Approved
E6201E6201 may decrease the antihypertensive activities of Betaxolol.Investigational
EbselenEbselen may decrease the antihypertensive activities of Betaxolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Betaxolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Betaxolol.Approved
EfonidipineBetaxolol may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Betaxolol.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Betaxolol.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Betaxolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Enalapril.Approved, Vet Approved
EnalaprilatBetaxolol may increase the hypotensive activities of Enalaprilat.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Betaxolol.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Betaxolol.Investigational
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Nutraceutical, Withdrawn
EPIBATIDINEThe risk or severity of adverse effects can be increased when Betaxolol is combined with EPIBATIDINE.Experimental
EpinastineThe metabolism of Epinastine can be decreased when combined with Betaxolol.Approved, Investigational
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Betaxolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Betaxolol is combined with Eplerenone.Approved
EpoprostenolBetaxolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Betaxolol is combined with Eprosartan.Approved
Ergoloid mesylateBetaxolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineBetaxolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Betaxolol.Approved, Investigational
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Betaxolol.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Betaxolol.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Betaxolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Betaxolol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Betaxolol.Approved, Illicit
EtodolacEtodolac may decrease the antihypertensive activities of Betaxolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Betaxolol.Approved
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
EtoperidoneThe serum concentration of Betaxolol can be increased when it is combined with Etoperidone.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Betaxolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Betaxolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Betaxolol.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Betaxolol.Approved
FenoldopamBetaxolol may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Betaxolol.Approved
FenoterolBetaxolol may decrease the bronchodilatory activities of Fenoterol.Approved
FentanylFentanyl may increase the bradycardic activities of Betaxolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Betaxolol.Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Betaxolol.Approved
FimasartanThe risk or severity of adverse effects can be increased when Betaxolol is combined with Fimasartan.Approved
FingolimodBetaxolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Betaxolol.Approved, Withdrawn
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Betaxolol.Approved, Withdrawn
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Betaxolol.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Betaxolol.Vet Approved
FluoxetineThe metabolism of Betaxolol can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Betaxolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Betaxolol.Approved
FluvoxamineThe metabolism of Betaxolol can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Betaxolol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Fosinopril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Betaxolol.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Furosemide.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Betaxolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Betaxolol.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Betaxolol.Approved, Investigational
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Betaxolol.Approved, Nutraceutical
GlibornurideBetaxolol may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideBetaxolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideBetaxolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideBetaxolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneBetaxolol may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideBetaxolol may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideBetaxolol may increase the hypoglycemic activities of Glyburide.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Betaxolol.Approved, Investigational
GTS-21The risk or severity of adverse effects can be increased when Betaxolol is combined with GTS-21.Investigational
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
GuanadrelBetaxolol may increase the hypotensive activities of Guanadrel.Approved
GuanethidineBetaxolol may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Investigational
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Betaxolol.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Betaxolol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Betaxolol.Approved, Vet Approved
HexamethoniumBetaxolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Betaxolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Betaxolol.Investigational
HMPL-004HMPL-004 may decrease the antihypertensive activities of Betaxolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Betaxolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Betaxolol.Approved
HydralazineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Betaxolol.Approved, Illicit
HydroflumethiazideBetaxolol may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Betaxolol.Approved, Illicit
HydroxychloroquineThe metabolism of Betaxolol can be decreased when combined with Hydroxychloroquine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Betaxolol.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Betaxolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Betaxolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Betaxolol.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Betaxolol.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Betaxolol.Approved
IloprostIloprost may increase the hypotensive activities of Betaxolol.Approved, Investigational
ImatinibThe metabolism of Imatinib can be decreased when combined with Betaxolol.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Betaxolol.Approved
IndacaterolBetaxolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Betaxolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Indapamide.Approved
IndenololBetaxolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Betaxolol can be decreased when combined with Indinavir.Approved
IndomethacinIndomethacin may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Betaxolol.Withdrawn
IndoraminBetaxolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin PorkBetaxolol may increase the hypoglycemic activities of Insulin Pork.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Betaxolol.Approved
IproclozideIproclozide may increase the hypotensive activities of Betaxolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Betaxolol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Betaxolol is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Betaxolol.Approved
IsoetarineBetaxolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Betaxolol is combined with Isoflurane.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Betaxolol.Approved, Withdrawn
IsoniazidThe metabolism of Betaxolol can be decreased when combined with Isoniazid.Approved
IsoprenalineBetaxolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Betaxolol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Betaxolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Betaxolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Isradipine.Approved
IvabradineBetaxolol may increase the bradycardic activities of Ivabradine.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Betaxolol.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Betaxolol.Experimental
KetanserinBetaxolol may increase the hypotensive activities of Ketanserin.Investigational
KetoconazoleThe metabolism of Betaxolol can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Betaxolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Betaxolol.Approved
LabetalolBetaxolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineBetaxolol may increase the hypotensive activities of Lacidipine.Approved
LacosamideBetaxolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LanreotideBetaxolol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostBetaxolol may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
LercanidipineBetaxolol may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Levobupivacaine.Approved
LevodopaBetaxolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Betaxolol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Betaxolol is combined with Levosimendan.Approved, Investigational
LidocaineThe metabolism of Betaxolol can be decreased when combined with Lidocaine.Approved, Vet Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Betaxolol.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Betaxolol.Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Betaxolol.Approved
LobelineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Betaxolol.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Betaxolol.Approved
LopinavirThe metabolism of Betaxolol can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Betaxolol.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Betaxolol.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Betaxolol.Approved
LosartanThe risk or severity of adverse effects can be increased when Betaxolol is combined with Losartan.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Betaxolol.Approved
LucinactantBetaxolol may increase the bradycardic activities of Lucinactant.Approved
LumefantrineThe metabolism of Betaxolol can be decreased when combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
MacitentanBetaxolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Betaxolol.Approved
MalathionMalathion may increase the bradycardic activities of Betaxolol.Approved, Investigational
ManidipineBetaxolol may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Betaxolol is combined with Mannitol.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Betaxolol.Approved
MasoprocolMasoprocol may decrease the antihypertensive activities of Betaxolol.Approved
MebanazineMebanazine may increase the hypotensive activities of Betaxolol.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Betaxolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Betaxolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Betaxolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Betaxolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Betaxolol.Approved, Investigational
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Betaxolol.Investigational, Withdrawn
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Betaxolol.Approved, Vet Approved
MequitazineThe metabolism of Mequitazine can be decreased when combined with Betaxolol.Approved
MesalazineMesalazine may decrease the antihypertensive activities of Betaxolol.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Betaxolol.Approved
MetamizoleMetamizole may decrease the antihypertensive activities of Betaxolol.Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Methacholine.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Betaxolol.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Betaxolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Betaxolol.Approved
MethotrimeprazineThe metabolism of Betaxolol can be decreased when combined with Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Betaxolol.Approved, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Betaxolol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Betaxolol.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Betaxolol.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Betaxolol.Approved, Illicit, Withdrawn
MetipranololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Metipranolol.Approved
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Betaxolol.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Betaxolol is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Betaxolol.Approved, Investigational
MetyrosineBetaxolol may increase the hypotensive activities of Metyrosine.Approved
MexiletineThe metabolism of Betaxolol can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Betaxolol.Approved
MibefradilBetaxolol may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrineBetaxolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Betaxolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Betaxolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Minoxidil.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Betaxolol.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Betaxolol.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Betaxolol.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Betaxolol.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Betaxolol.Approved
MoricizineMoricizine may increase the hypotensive activities of Betaxolol.Approved, Withdrawn
MorphineThe metabolism of Morphine can be decreased when combined with Betaxolol.Approved, Investigational
MoxonidineBetaxolol may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Betaxolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Betaxolol.Approved
NadololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Betaxolol.Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Betaxolol.Approved
NaftopidilBetaxolol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Betaxolol.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Betaxolol.Approved, Investigational
NCX 4016NCX 4016 may decrease the antihypertensive activities of Betaxolol.Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Betaxolol.Approved, Investigational
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Betaxolol.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Betaxolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Betaxolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nesiritide.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Betaxolol.Approved
NevirapineThe metabolism of Betaxolol can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Betaxolol.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nicardipine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Betaxolol.Approved
NicorandilNicorandil may increase the hypotensive activities of Betaxolol.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Betaxolol.Approved
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nicotine bitartrate.Approved
NifedipineNifedipine may increase the hypotensive activities of Betaxolol.Approved
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Betaxolol.Approved
NiguldipineBetaxolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Betaxolol can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineBetaxolol may increase the hypotensive activities of Nilvadipine.Approved
NimesulideNimesulide may decrease the antihypertensive activities of Betaxolol.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nisoldipine.Approved
NitrendipineBetaxolol may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Betaxolol.Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Betaxolol.Approved, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nitroprusside.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Betaxolol.Approved
ObinutuzumabBetaxolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Betaxolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Betaxolol.Approved, Investigational
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Betaxolol.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Betaxolol is combined with Olmesartan.Approved, Investigational
OlodaterolBetaxolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Betaxolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Betaxolol.Approved
OmapatrilatBetaxolol may increase the hypotensive activities of Omapatrilat.Investigational
OndansetronThe metabolism of Ondansetron can be decreased when combined with Betaxolol.Approved
OrciprenalineBetaxolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Betaxolol.Vet Approved
OsimertinibThe serum concentration of Betaxolol can be decreased when it is combined with Osimertinib.Approved
OuabainBetaxolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Betaxolol.Approved
OxprenololBetaxolol may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Betaxolol.Approved, Illicit, Investigational
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Betaxolol.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Betaxolol.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Betaxolol is combined with Paclitaxel.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Betaxolol.Approved, Investigational
PanobinostatThe serum concentration of Betaxolol can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Papaverine.Approved
ParecoxibParecoxib may decrease the antihypertensive activities of Betaxolol.Approved
PargylinePargyline may increase the hypotensive activities of Betaxolol.Approved
ParoxetineThe metabolism of Betaxolol can be decreased when combined with Paroxetine.Approved, Investigational
PasireotideBetaxolol may increase the bradycardic activities of Pasireotide.Approved
PazopanibThe metabolism of Pazopanib can be decreased when combined with Betaxolol.Approved
Peginterferon alfa-2bThe serum concentration of Betaxolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Penbutolol.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be decreased when combined with Betaxolol.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Betaxolol.Approved, Vet Approved
PentoliniumBetaxolol may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Betaxolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Betaxolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Betaxolol.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Perindopril.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Betaxolol.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Betaxolol.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Betaxolol.Withdrawn
PhenelzinePhenelzine may increase the hypotensive activities of Betaxolol.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Betaxolol.Approved, Withdrawn
PheniprazinePheniprazine may increase the hypotensive activities of Betaxolol.Withdrawn
PhenobarbitalThe metabolism of Betaxolol can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineBetaxolol may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Betaxolol.Withdrawn
PhentolamineBetaxolol may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Betaxolol.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Betaxolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
PinacidilBetaxolol may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Betaxolol is combined with Pipamperone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Betaxolol.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Betaxolol.Approved
PirbuterolBetaxolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Betaxolol.Investigational
PirlindolePirlindole may increase the hypotensive activities of Betaxolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Betaxolol.Withdrawn
PolythiazideBetaxolol may increase the hypotensive activities of Polythiazide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Betaxolol.Approved
Poractant alfaBetaxolol may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Betaxolol is combined with Pramipexole.Approved, Investigational
PrazosinBetaxolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Betaxolol can be decreased when combined with Primaquine.Approved
PrimidoneThe metabolism of Betaxolol can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Betaxolol.Approved
ProcaterolBetaxolol may decrease the bronchodilatory activities of Procaterol.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Betaxolol.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Betaxolol.Approved, Vet Approved
PromazineThe metabolism of Betaxolol can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Betaxolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Betaxolol.Approved
PropafenoneThe serum concentration of Betaxolol can be increased when it is combined with Propafenone.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Betaxolol.Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Betaxolol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Propranolol.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Betaxolol.Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Betaxolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Betaxolol.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Quinapril.Approved, Investigational
QuinidineThe metabolism of Betaxolol can be decreased when combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Betaxolol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Betaxolol.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Betaxolol.Approved
RanolazineThe metabolism of Betaxolol can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Betaxolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Betaxolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Remifentanil.Approved
RemikirenBetaxolol may increase the hypotensive activities of Remikiren.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Betaxolol.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Betaxolol.Investigational
RescinnamineBetaxolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Betaxolol.Approved
ResveratrolResveratrol may decrease the antihypertensive activities of Betaxolol.Experimental, Investigational
RifampicinThe metabolism of Betaxolol can be increased when combined with Rifampicin.Approved
RifapentineThe serum concentration of Betaxolol can be decreased when it is combined with Rifapentine.Approved
RilmenidineBetaxolol may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Betaxolol is combined with Riociguat.Approved
RisperidoneBetaxolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineBetaxolol may decrease the bronchodilatory activities of Ritodrine.Approved
RitonavirThe metabolism of Betaxolol can be decreased when combined with Ritonavir.Approved, Investigational
RituximabBetaxolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Betaxolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Betaxolol.Investigational, Withdrawn
RolapitantThe metabolism of Betaxolol can be decreased when combined with Rolapitant.Approved
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Betaxolol.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Betaxolol.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Betaxolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Betaxolol.Withdrawn
SalbutamolBetaxolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Betaxolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Betaxolol.Approved, Vet Approved
SalmeterolBetaxolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Betaxolol.Approved
SaprisartanBetaxolol may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Betaxolol.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Betaxolol.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Betaxolol.Approved, Investigational, Vet Approved
SelexipagBetaxolol may increase the hypotensive activities of Selexipag.Approved
SeratrodastSeratrodast may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Betaxolol.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Betaxolol.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Betaxolol is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Betaxolol.Approved, Investigational
SilodosinBetaxolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SimeprevirThe metabolism of Betaxolol can be decreased when combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Betaxolol.Approved
SitaxentanBetaxolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Betaxolol is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Betaxolol is combined with Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Betaxolol.Experimental
SpiraprilBetaxolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Betaxolol is combined with Spironolactone.Approved
SRT501SRT501 may decrease the antihypertensive activities of Betaxolol.Investigational
StiripentolThe metabolism of Betaxolol can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Betaxolol is combined with Streptokinase.Approved
SufentanilBetaxolol may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Betaxolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Betaxolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Betaxolol.Approved, Withdrawn
TacrineTacrine may increase the bradycardic activities of Betaxolol.Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Betaxolol.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Betaxolol resulting in a loss in efficacy.Approved
TamsulosinBetaxolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Betaxolol.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Betaxolol.Investigational, Withdrawn
TelmisartanThe risk or severity of adverse effects can be increased when Betaxolol is combined with Telmisartan.Approved, Investigational
TemocaprilBetaxolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenofovirThe metabolism of Betaxolol can be decreased when combined with Tenofovir.Approved, Investigational
TenoxicamTenoxicam may decrease the antihypertensive activities of Betaxolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Betaxolol.Vet Approved
TerazosinBetaxolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Betaxolol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineBetaxolol may decrease the bronchodilatory activities of Terbutaline.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Betaxolol.Withdrawn
TeriflunomideThe serum concentration of Betaxolol can be decreased when it is combined with Teriflunomide.Approved
TerlipressinBetaxolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Betaxolol.Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Betaxolol.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Betaxolol can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Betaxolol.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Betaxolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Betaxolol.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Betaxolol.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Betaxolol.Approved
TiboloneBetaxolol may increase the hypotensive activities of Tibolone.Approved
TiclopidineThe metabolism of Betaxolol can be decreased when combined with Ticlopidine.Approved
TicrynafenBetaxolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Timolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Betaxolol.Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Betaxolol.Approved
TipranavirThe metabolism of Betaxolol can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Betaxolol.Approved, Investigational
TolazamideBetaxolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineBetaxolol may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideBetaxolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Betaxolol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Betaxolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Betaxolol.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Betaxolol.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Betaxolol.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Betaxolol is combined with Torasemide.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Betaxolol.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Betaxolol.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Trandolapril.Approved
TranilastTranilast may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Betaxolol.Experimental
TranylcypromineThe metabolism of Betaxolol can be decreased when combined with Tranylcypromine.Approved
TravoprostBetaxolol may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Betaxolol.Approved, Investigational
TreprostinilBetaxolol may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Betaxolol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Betaxolol is combined with Triamterene.Approved
TrichlorfonTrichlorfon may increase the bradycardic activities of Betaxolol.Vet Approved
TrichlormethiazideBetaxolol may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Betaxolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Betaxolol.Approved, Vet Approved
TrimazosinBetaxolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanBetaxolol may increase the hypotensive activities of Trimethaphan.Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Betaxolol.Approved
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Betaxolol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Betaxolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Betaxolol.Approved, Investigational
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Betaxolol.Approved
UnoprostoneBetaxolol may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibValdecoxib may decrease the antihypertensive activities of Betaxolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Betaxolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Betaxolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Betaxolol is combined with Varenicline.Approved, Investigational
VemurafenibThe serum concentration of Betaxolol can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Betaxolol can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Betaxolol is combined with Verapamil.Approved
VilanterolBetaxolol may decrease the bronchodilatory activities of Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Betaxolol.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Betaxolol.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Betaxolol.Approved, Investigational
VinpocetineBetaxolol may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Betaxolol.Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Betaxolol.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Betaxolol.Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Betaxolol.Approved
ZileutonZileuton may decrease the antihypertensive activities of Betaxolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Betaxolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Betaxolol can be decreased when combined with Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Betaxolol.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Betaxolol.Withdrawn
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Betaxolol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Ramesh Joshi, Muthukrishnan Murugan, Dinesh Garud, Sanjay Borikar, Mukund Gurjar, “PROCESS FOR PREPARATION OF S-(-)-BETAXOLOL AND SALTS THEREOF.” U.S. Patent US20060004109, issued January 05, 2006.

US20060004109
General References
  1. Canotilho J, Castro RA: The structure of betaxolol studied by infrared spectroscopy and natural bond orbital theory. Spectrochim Acta A Mol Biomol Spectrosc. 2010 Aug;76(3-4):395-400. doi: 10.1016/j.saa.2010.03.038. Epub 2010 Apr 4. [PubMed:20418154 ]
External Links
ATC CodesC07AB05S01ED52S01ED02
AHFS Codes
  • 52:92.00
PDB EntriesNot Available
FDA labelDownload (111 KB)
MSDSDownload (38.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9903
Blood Brain Barrier-0.8906
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.7683
P-glycoprotein inhibitor INon-inhibitor0.7967
P-glycoprotein inhibitor IINon-inhibitor0.8547
Renal organic cation transporterNon-inhibitor0.8206
CYP450 2C9 substrateNon-substrate0.8106
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.7221
CYP450 1A2 substrateInhibitor0.8972
CYP450 2C9 inhibitorInhibitor0.5241
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9249
CYP450 3A4 inhibitorNon-inhibitor0.9647
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9741
Ames testNon AMES toxic0.8765
CarcinogenicityNon-carcinogens0.9304
BiodegradationNot ready biodegradable0.9395
Rat acute toxicity2.1620 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7663
hERG inhibition (predictor II)Non-inhibitor0.7498
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Akorn inc
  • Bausch and lomb pharmaceuticals inc
  • Novex pharma
  • Wockhardt ltd
  • Alcon laboratories inc
  • Epic pharma llc
  • Kvk tech inc
  • Sanofi aventis us llc
  • Alcon inc
Packagers
Dosage forms
FormRouteStrength
Solution / dropsOphthalmic5 mg/mL
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
Solution / dropsOphthalmic5.6 mg/mL
Tablet, coatedOral10 mg/1
Tablet, coatedOral20 mg/1
LiquidOphthalmic0.5 %
Suspension / dropsOphthalmic2.8 mg/mL
SuspensionOphthalmic.25 %
SuspensionOphthalmic
SolutionOphthalmic0.5 %
Prices
Unit descriptionCostUnit
Betoptic-S 0.25% Suspension 15ml Bottle195.44USD bottle
Betoptic-S 0.25% Suspension 10ml Bottle130.29USD bottle
Betaxolol HCl 0.5% Solution 15ml Bottle104.31USD bottle
Betoptic-S 0.25% Suspension 5ml Bottle51.99USD bottle
Betoptic s 0.25% eye drops9.79USD ml
Betaxolol hcl 0.5% eye drop6.82USD ml
Betoptic S 0.25 % Suspension2.54USD ml
Kerlone 20 mg tablet2.35USD tablet
Betaxolol 20 mg tablet1.86USD tablet
Kerlone 10 mg tablet1.63USD tablet
Betaxolol HCl 10 mg tablet1.29USD tablet
Betaxolol 10 mg tablet1.24USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5540918 No1994-01-302014-01-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point70-72 °CPhysProp
water solubility451 mg/LNot Available
logP2.81RECANATINI,M (1992)
Caco2 permeability-4.81ADME Research, USCD
pKa9.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0298 mg/mLALOGPS
logP3ALOGPS
logP2.54ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area50.72 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity88.64 m3·mol-1ChemAxon
Polarizability37.05 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tyrosols and derivatives. These are compounds containing a hydroxyethyl group attached to the C4 carbon of a phenol group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenols and derivatives
Direct ParentTyrosols and derivatives
Alternative Parents
Substituents
  • Tyrosol derivative
  • Phenol ether
  • Alkyl aryl ether
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. McLean AJ, Zeng FY, Behan D, Chalmers D, Milligan G: Generation and analysis of constitutively active and physically destabilized mutants of the human beta(1)-adrenoceptor. Mol Pharmacol. 2002 Sep;62(3):747-55. [PubMed:12181453 ]
  2. Rudoy CA, Van Bockstaele EJ: Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1119-29. Epub 2007 Apr 19. [PubMed:17513029 ]
  3. Satoh N, Suzuki J, Bessho H, Kitada Y, Narimatsu A, Tobe A: Effects of betaxolol on cardiohemodynamics and coronary circulation in anesthetized dogs: comparison with atenolol and propranolol. Jpn J Pharmacol. 1990 Oct;54(2):113-9. [PubMed:2077180 ]
  4. Lesar TS: Comparison of ophthalmic beta-blocking agents. Clin Pharm. 1987 Jun;6(6):451-63. [PubMed:2891463 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Rait JL: Systemic effects of topical ophthalmic beta-adrenoceptor antagonists. Aust N Z J Ophthalmol. 1999 Feb;27(1):57-64. [PubMed:10080340 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23